Skip to search formSkip to main contentSkip to account menu

mafosfamide

Known as: 2-((2-(bis(2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorin-4-yl)thio)ethanesulfonic acid P-oxide 
A synthetic oxazaphosphorine derivative with antineoplastic properties. Mafosfamide alkylates DNA, forming DNA cross-links and inhibiting DNA… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2014
Review
2014
PURPOSE To date, response criteria and optimal methods for assessment of outcome have not been standardized in patients with… 
Highly Cited
2014
Highly Cited
2014
Aldehyde dehydrogenase enzymes irreversibly oxidize aldehydes generated from metabolism of amino acids, fatty acids, food, smoke… 
Highly Cited
2006
Highly Cited
2006
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the… 
Highly Cited
2005
Highly Cited
2005
PURPOSE Preclinical studies of mafosfamide, a preactivated cyclophosphamide analog, were performed to define a tolerable and… 
Review
1999
Review
1999
  • S. Ludeman
  • Current pharmaceutical design
  • 1999
  • Corpus ID: 38642884
This is primarily an overview of the spontaneous (non-enzymatic) chemistry of the metabolites of cyclophosphamide, viz., cis- and… 
Highly Cited
1993
Highly Cited
1993
Synthetic oligodeoxynucleotides complementary to the break-point junction of bcr-abl transcripts selectively inhibit the… 
Highly Cited
1991
Highly Cited
1991
Fifty-nine European teams have reported 919 autografts for the consolidation of acute myelocytic leukemia (AML) up to December 31… 
Review
1990
Review
1990
We analyzed data from 263 patients with acute myelocytic leukemia (AML) autografted in first remission (CR) during the period… 
Highly Cited
1990
Highly Cited
1990
The knowledge about drug resistance in childhood leukemias and acute lymphoblastic leukemia (ALL) in general is limited. This is…